SCHEMBL10324944

SCHEMBL10324944

CC(N)(CCC(=O)O)P(=O)(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
THRB P10828 1/20 0.45
KMT2A Q03164 1/20 0.45
FDPS P14324 5/20 0.42
GRM4 Q14833 1/20 0.40
NAALAD2 Q9Y3Q0 1/20 0.39
ESR1 P03372 1/20 0.36
CYP3A4 P08684 1/20 0.36
ESR2 Q92731 1/20 0.36
SMPD1 P17405 2/20 0.35
CHEK1 O14757 1/20 0.34
FYN P06241 1/20 0.34
PDGFRB P09619 1/20 0.34
PIM1 P11309 1/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
GRK5 P34947 1/20 0.34
MAP2K2 P36507 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20533249 1.00 ALDH1A1 (0.45) ALDH1A1MEN1CYP1A2THRBKMT2A
SCHEMBL9308664 0.77 FDPS (0.46) ALDH1A1MEN1KMT2AFDPSGRM4
SCHEMBL9802369 0.77 FDPS (0.41) FDPSGRM4SMPD1LMNA
SCHEMBL10360956 0.76 NAALAD2 (0.41) ALDH1A1MEN1CYP1A2THRBKMT2A
SCHEMBL27771082 0.75 ALDH1A1 (0.43) ALDH1A1MEN1CYP1A2THRBKMT2A
SCHEMBL6770526 0.75 FDPS (0.48) FDPSGRM4SMPD1LMNA
SCHEMBL5918828 0.75 FDPS (0.62) FDPSGRM4SMPD1
SCHEMBL3379180 0.74 MEN1 (0.41) ALDH1A1MEN1CYP1A2THRBKMT2A
SCHEMBL7111437 0.74 NAALAD2 (0.44) ALDH1A1MEN1CYP1A2THRBKMT2A
SCHEMBL1933286 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140271926-A1 METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS CALIFORNIA INSTITUTE OF TECHNOLOGY 2014-09-18 US claimed
EP-4541812-A2 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION Sanofi (FR) 2025-04-23 EP disclosed
EP-4214308-B1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION SANOFI SA (FR) 2024-11-20 EP disclosed
EP-4419094-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS Edison Oncology (US) 2024-08-28 EP disclosed
US-20240043878-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION SANOFI (FR) 2024-02-08 US disclosed
EP-4214308-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION Sanofi (FR) 2023-07-26 EP disclosed
WO-2023069727-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS EDISON ONCOLOGY (US) 2023-04-27 WO disclosed
WO-2022058603-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION SANOFI (FR) 2022-03-24 WO disclosed
US-10947598-B2 Methods for determining the metabolic status of lymphomas INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2021-03-16 US disclosed
EP-3356551-B1 METHODS FOR DETERMINING THE METABOLIC STATUS OF B-LYMPHOMAS INST NAT SANTE RECH MED (FR) 2020-09-02 EP disclosed
US-20180282816-A1 METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS Université Côte d'Azur (FR) 2018-10-04 US disclosed
EP-3356551-A1 METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-08-08 EP disclosed
US-20140271926-A1 METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS CALIFORNIA INSTITUTE OF TECHNOLOGY 2014-09-18 US disclosed
WO-2012095514-A1 RECOMBINANT PROTEIN PRODUCTION SYSTEM VIVALIS (FR) 2012-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10947598-B2 Methods for determining the metabolic status of lymphomas GAPDH, GCDH, IDH2 ALDH1A1 571/4885MEN1 4447/4885CYP1A2 998/4885
US-20240043878-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION DHODH, GLUL, GLS2 ALDH1A1 1617/4885MEN1 2961/4885CYP1A2 2401/4885
US-20180282816-A1 METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS GAPDH, IDH2, GCDH ALDH1A1 416/4885MEN1 4454/4885CYP1A2 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.